VIR Form 144: 1668404 Shares Proposed Sale on NASDAQ

Rhea-AI Filing Summary

Vir Biotechnology, Inc. submitted a Form 144 notifying a proposed sale of 1668404 shares of its Common Stock through BTIG, LLC on the NASDAQ with an approximate aggregate market value of $9526586.84. The filing shows the shares were originally acquired on 10/16/2019 upon automatic conversion of convertible preferred stock that had been purchased between August 2017 and January 2019, with 21666666 shares noted as the amount acquired and 01/31/2019 listed as a payment date. The issuer's total shares outstanding are listed as 138916426, and the proposed approximate sale date is 10/03/2025. The filer represents there are no undisclosed material adverse facts and indicates no securities were sold by this person in the past three months.

Positive

• Brokered sale disclosed through BTIG, LLC with exchange listed as NASDAQ
• Acquisition provenance provided: shares arose from automatic conversion on 10/16/2019 of convertible preferred stock
• No securities sold in past 3 months reported for the selling person

Negative

• Proposed sizeable sale of 1668404 shares with aggregate value $9526586.84
• Large original holding is shown: 21666666 shares were acquired previously (conversion)

Insights

Securities Compliance Expert

Form 144 documents a proposed Rule 144 sale via BTIG of 1668404 Vir shares on 10/03/2025.

The filing follows Rule 144 disclosure requirements by naming the broker (BTIG, LLC), the class (Common Stock), the number of shares (1668404), the aggregate value ($9526586.84), and the intended exchange (NASDAQ).

It also discloses acquisition provenance: the shares were received on 10/16/2019 via automatic conversion of convertible preferred stock acquired from August 2017 to January 2019, with 21666666 shares recorded as acquired and 01/31/2019 as a payment date. This information supports Rule 144 eligibility claims by documenting holding origin and purchase timing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/03/2025 - 05:00 PM Learn about SEC filing dates

FAQ

What does Vir Biotechnology's (VIR) Form 144 disclose?

The filing discloses a proposed sale of 1668404 shares of common stock valued at $9526586.84, to be brokered by BTIG, LLC on NASDAQ with an approximate sale date of 10/03/2025.

Who is the broker handling the VIR share sale reported on Form 144?

The broker named in the filing is BTIG, LLC, located at 350 Bush Street, 9th Floor San Francisco, CA 94104.

When were the shares to be sold originally acquired according to the filing?

The shares were acquired on 10/16/2019 upon automatic conversion of convertible preferred stock that had been acquired between August 2017 and January 2019.

How many Vir shares are outstanding per the Form 144?

The filing lists total shares outstanding as 138916426.

Did the filer report any sales of Vir securities in the past three months?

The filing states Nothing to Report for securities sold by the person in the past three months.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	BTIG, LLC 350 Bush Street, 9th Floor San Francisco, CA 94104	1668404	9526586.84	138916426	10/03/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	10/16/2019	Acquired upon the automatic conversion of convertible preferred stock. The convertible preferred stock was acquired and fully paid for in multiple transactions from August 2017 to January 2019.	Issuer			21666666	01/31/2019	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)